The administration of human amniotic epithelial cells in premature ovarian insufficiency: From preclinical to clinical
Premature ovarian insufficiency (POI) or premature ovarian failure (POF) is a multifactorial disorder occurring in reproductive-age women, characterized by elevated levels of follicle-stimulating hormone (FSH) and irregular or absent menstrual cycles, often accompanied by perimenopausal symptoms and...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Gynecological Endocrinology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09513590.2024.2382818 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850243353068699648 |
|---|---|
| author | Xiaojing Zhao Zhongna Yu Xinrun Wang Xiaojing Li Yang Liu Liang Wang |
| author_facet | Xiaojing Zhao Zhongna Yu Xinrun Wang Xiaojing Li Yang Liu Liang Wang |
| author_sort | Xiaojing Zhao |
| collection | DOAJ |
| description | Premature ovarian insufficiency (POI) or premature ovarian failure (POF) is a multifactorial disorder occurring in reproductive-age women, characterized by elevated levels of follicle-stimulating hormone (FSH) and irregular or absent menstrual cycles, often accompanied by perimenopausal symptoms and infertility. While assisted reproductive technology can address the reproductive aspirations of some POI-affected women, it is hindered by issues such as exorbitant expenses, substantial risks, and poor rates of conception. Encouragingly, extensive research is exploring novel approaches to enhance fertility, particularly in the realm of stem cell therapy, showcasing both feasibility and significant potential. Human amniotic epithelial cells (hAECs) from discarded placental tissues are crucial in regenerative medicine for their pluripotency, low immunogenicity, non-tumorigenicity, accessibility, and minimal ethical concerns. Preclinical studies highlight the underlying mechanisms and therapeutic effects of hAECs in POI treatment, and current research is focusing on innovative interventions to augment hAECs’ efficacy. However, despite these strides, overcoming application challenges is essential for successful clinical translation. This paper conducted a comprehensive analysis of the aforementioned issues, examining the prospects and challenges of hAECs in POI, with the aim of providing some insights for future research and clinical practice. |
| format | Article |
| id | doaj-art-a527b588e0884f9fab211cfcd800731b |
| institution | OA Journals |
| issn | 0951-3590 1473-0766 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Gynecological Endocrinology |
| spelling | doaj-art-a527b588e0884f9fab211cfcd800731b2025-08-20T02:00:02ZengTaylor & Francis GroupGynecological Endocrinology0951-35901473-07662024-12-0140110.1080/09513590.2024.2382818The administration of human amniotic epithelial cells in premature ovarian insufficiency: From preclinical to clinicalXiaojing Zhao0Zhongna Yu1Xinrun Wang2Xiaojing Li3Yang Liu4Liang Wang5Department of Gynecology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaDepartment of Gynecology, The Affiliated People’s Hospital, Ningbo University, Ningbo, Zhejiang, ChinaDepartment of Gynecology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaDepartment of Gynecology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaDepartment of Gynecology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaDepartment of Gynecology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaPremature ovarian insufficiency (POI) or premature ovarian failure (POF) is a multifactorial disorder occurring in reproductive-age women, characterized by elevated levels of follicle-stimulating hormone (FSH) and irregular or absent menstrual cycles, often accompanied by perimenopausal symptoms and infertility. While assisted reproductive technology can address the reproductive aspirations of some POI-affected women, it is hindered by issues such as exorbitant expenses, substantial risks, and poor rates of conception. Encouragingly, extensive research is exploring novel approaches to enhance fertility, particularly in the realm of stem cell therapy, showcasing both feasibility and significant potential. Human amniotic epithelial cells (hAECs) from discarded placental tissues are crucial in regenerative medicine for their pluripotency, low immunogenicity, non-tumorigenicity, accessibility, and minimal ethical concerns. Preclinical studies highlight the underlying mechanisms and therapeutic effects of hAECs in POI treatment, and current research is focusing on innovative interventions to augment hAECs’ efficacy. However, despite these strides, overcoming application challenges is essential for successful clinical translation. This paper conducted a comprehensive analysis of the aforementioned issues, examining the prospects and challenges of hAECs in POI, with the aim of providing some insights for future research and clinical practice.https://www.tandfonline.com/doi/10.1080/09513590.2024.2382818Premature ovarian insufficiency (POI)premature ovarian failure (POF)human amniotic epithelial cells (hAECs)underlying mechanismsclinical translation |
| spellingShingle | Xiaojing Zhao Zhongna Yu Xinrun Wang Xiaojing Li Yang Liu Liang Wang The administration of human amniotic epithelial cells in premature ovarian insufficiency: From preclinical to clinical Gynecological Endocrinology Premature ovarian insufficiency (POI) premature ovarian failure (POF) human amniotic epithelial cells (hAECs) underlying mechanisms clinical translation |
| title | The administration of human amniotic epithelial cells in premature ovarian insufficiency: From preclinical to clinical |
| title_full | The administration of human amniotic epithelial cells in premature ovarian insufficiency: From preclinical to clinical |
| title_fullStr | The administration of human amniotic epithelial cells in premature ovarian insufficiency: From preclinical to clinical |
| title_full_unstemmed | The administration of human amniotic epithelial cells in premature ovarian insufficiency: From preclinical to clinical |
| title_short | The administration of human amniotic epithelial cells in premature ovarian insufficiency: From preclinical to clinical |
| title_sort | administration of human amniotic epithelial cells in premature ovarian insufficiency from preclinical to clinical |
| topic | Premature ovarian insufficiency (POI) premature ovarian failure (POF) human amniotic epithelial cells (hAECs) underlying mechanisms clinical translation |
| url | https://www.tandfonline.com/doi/10.1080/09513590.2024.2382818 |
| work_keys_str_mv | AT xiaojingzhao theadministrationofhumanamnioticepithelialcellsinprematureovarianinsufficiencyfrompreclinicaltoclinical AT zhongnayu theadministrationofhumanamnioticepithelialcellsinprematureovarianinsufficiencyfrompreclinicaltoclinical AT xinrunwang theadministrationofhumanamnioticepithelialcellsinprematureovarianinsufficiencyfrompreclinicaltoclinical AT xiaojingli theadministrationofhumanamnioticepithelialcellsinprematureovarianinsufficiencyfrompreclinicaltoclinical AT yangliu theadministrationofhumanamnioticepithelialcellsinprematureovarianinsufficiencyfrompreclinicaltoclinical AT liangwang theadministrationofhumanamnioticepithelialcellsinprematureovarianinsufficiencyfrompreclinicaltoclinical AT xiaojingzhao administrationofhumanamnioticepithelialcellsinprematureovarianinsufficiencyfrompreclinicaltoclinical AT zhongnayu administrationofhumanamnioticepithelialcellsinprematureovarianinsufficiencyfrompreclinicaltoclinical AT xinrunwang administrationofhumanamnioticepithelialcellsinprematureovarianinsufficiencyfrompreclinicaltoclinical AT xiaojingli administrationofhumanamnioticepithelialcellsinprematureovarianinsufficiencyfrompreclinicaltoclinical AT yangliu administrationofhumanamnioticepithelialcellsinprematureovarianinsufficiencyfrompreclinicaltoclinical AT liangwang administrationofhumanamnioticepithelialcellsinprematureovarianinsufficiencyfrompreclinicaltoclinical |